Treatment and outcomes of a Danish ovarian cancer population

Tobias Berg; Trine J Nøttrup; Ulla B S Peen; Henrik Roed

Treatment and outcomes of a Danish ovarian cancer population

Department of Oncology

10 Citations (Scopus)

Abstract

INTRODUCTION: Ovarian cancer has the highest mortality rate among gynaecological cancers and is the tenth most frequent cancer among women. 80% of patients with advanced stage disease will experience a progression either during or after treatment.

METHODS: This was a retrospective, observational study of all women referred to adjuvant or neoadjuvant treatment for ovarian cancer between 1 June 2013 and 31 May 2014 at two university hospitals in Denmark.

RESULTS: We included 142 women diagnosed with ovarian cancer. The median overall survival from diagnosis was 48.5 months (95% confidence interval (CI): 36.6-57.9 months). Median survival after the first, second, third, fourth and fifth progression was 19.3 (95% CI: 13.9-27-3), 11.4 (95% CI: 7.7-18.8), 9.5 (95% CI: 6.3-12.7), 8.3 (95% CI: 7.6-11.5) and 5.6  (95% CI: 2.9-not assessed) months, respectively. Median progression-free survival from diagnosis was 15.6 months (95% CI: 14.3-18.4 months). Median progression-free survival after first, second, third, fourth and fifth progression was 9.2 (95% CI: 7.7-10.6), 6.0 (95% CI: 3.5-7.7), 3.3 (95% CI: 2.6-4.6), 4.9 (95% CI: 3.6-8.3) and 3.0 (95% CI: 2.4-5.7) months, respectively. The most frequently used treatment at first progression was carboplatin and pegylated liposomal doxorubicin (n = 37). The most used non-platinum containing treatment at progression was pegylated liposomal doxorubicin (n = 26) followed by paclitaxel (n = 23).

CONCLUSIONS: Ovarian cancer remains a highly aggressive disease with most patients diagnosed in advanced stages. Treatment has not changed much in the past 15 years and the same is evident for the overall survival.

FUNDING: Tobias Berg received an unrestricted research grant from the Danish Cancer Society.

TRIAL REGISTRATION: not relevant.

Original language	English
Journal	Danish Medical Bulletin
Volume	67
Issue number	1
ISSN	0907-8916
Publication status	Published - Jan 2020

Keywords

Adult
Aged
Antineoplastic Agents/therapeutic use
Carboplatin/therapeutic use
Denmark
Disease Progression
Doxorubicin/analogs & derivatives
Female
Humans
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Ovarian Neoplasms/mortality
Paclitaxel/therapeutic use
Polyethylene Glycols/therapeutic use
Retrospective Studies
Treatment Outcome

Cite this

@article{1a54343d7fc44827a96cd6309388e603,

title = "Treatment and outcomes of a Danish ovarian cancer population",

abstract = "INTRODUCTION: Ovarian cancer has the highest mortality rate among gynaecological cancers and is the tenth most frequent cancer among women. 80\% of patients with advanced stage disease will experience a progression either during or after treatment.METHODS: This was a retrospective, observational study of all women referred to adjuvant or neoadjuvant treatment for ovarian cancer between 1 June 2013 and 31 May 2014 at two university hospitals in Denmark.RESULTS: We included 142 women diagnosed with ovarian cancer. The median overall survival from diagnosis was 48.5 months (95\% confidence interval (CI): 36.6-57.9 months). Median survival after the first, second, third, fourth and fifth progression was 19.3 (95\% CI: 13.9-27-3), 11.4 (95\% CI: 7.7-18.8), 9.5 (95\% CI: 6.3-12.7), 8.3 (95\% CI: 7.6-11.5) and 5.6  (95\% CI: 2.9-not assessed) months, respectively. Median progression-free survival from diagnosis was 15.6 months (95\% CI: 14.3-18.4 months). Median progression-free survival after first, second, third, fourth and fifth progression was 9.2 (95\% CI: 7.7-10.6), 6.0 (95\% CI: 3.5-7.7), 3.3 (95\% CI: 2.6-4.6), 4.9 (95\% CI: 3.6-8.3) and 3.0 (95\% CI: 2.4-5.7) months, respectively. The most frequently used treatment at first progression was carboplatin and pegylated liposomal doxorubicin (n = 37). The most used non-platinum containing treatment at progression was pegylated liposomal doxorubicin (n = 26) followed by paclitaxel (n = 23).CONCLUSIONS: Ovarian cancer remains a highly aggressive disease with most patients diagnosed in advanced stages. Treatment has not changed much in the past 15 years and the same is evident for the overall survival.FUNDING: Tobias Berg received an unrestricted research grant from the Danish Cancer Society.TRIAL REGISTRATION: not relevant.",

keywords = "Adult, Aged, Antineoplastic Agents/therapeutic use, Carboplatin/therapeutic use, Denmark, Disease Progression, Doxorubicin/analogs \& derivatives, Female, Humans, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Ovarian Neoplasms/mortality, Paclitaxel/therapeutic use, Polyethylene Glycols/therapeutic use, Retrospective Studies, Treatment Outcome",

author = "Tobias Berg and N{\o}ttrup, \{Trine J\} and Peen, \{Ulla B S\} and Henrik Roed",

note = "Articles published in the DMJ are {\textquotedblleft}open access{\textquotedblright}. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.",

year = "2020",

month = jan,

language = "English",

volume = "67",

journal = "Danish Medical Bulletin",

issn = "0907-8916",

publisher = "Almindelige Danske L{\ae}geforening",

number = "1",

}

TY - JOUR

T1 - Treatment and outcomes of a Danish ovarian cancer population

AU - Berg, Tobias

AU - Nøttrup, Trine J

AU - Peen, Ulla B S

AU - Roed, Henrik

N1 - Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PY - 2020/1

Y1 - 2020/1

N2 - INTRODUCTION: Ovarian cancer has the highest mortality rate among gynaecological cancers and is the tenth most frequent cancer among women. 80% of patients with advanced stage disease will experience a progression either during or after treatment.METHODS: This was a retrospective, observational study of all women referred to adjuvant or neoadjuvant treatment for ovarian cancer between 1 June 2013 and 31 May 2014 at two university hospitals in Denmark.RESULTS: We included 142 women diagnosed with ovarian cancer. The median overall survival from diagnosis was 48.5 months (95% confidence interval (CI): 36.6-57.9 months). Median survival after the first, second, third, fourth and fifth progression was 19.3 (95% CI: 13.9-27-3), 11.4 (95% CI: 7.7-18.8), 9.5 (95% CI: 6.3-12.7), 8.3 (95% CI: 7.6-11.5) and 5.6  (95% CI: 2.9-not assessed) months, respectively. Median progression-free survival from diagnosis was 15.6 months (95% CI: 14.3-18.4 months). Median progression-free survival after first, second, third, fourth and fifth progression was 9.2 (95% CI: 7.7-10.6), 6.0 (95% CI: 3.5-7.7), 3.3 (95% CI: 2.6-4.6), 4.9 (95% CI: 3.6-8.3) and 3.0 (95% CI: 2.4-5.7) months, respectively. The most frequently used treatment at first progression was carboplatin and pegylated liposomal doxorubicin (n = 37). The most used non-platinum containing treatment at progression was pegylated liposomal doxorubicin (n = 26) followed by paclitaxel (n = 23).CONCLUSIONS: Ovarian cancer remains a highly aggressive disease with most patients diagnosed in advanced stages. Treatment has not changed much in the past 15 years and the same is evident for the overall survival.FUNDING: Tobias Berg received an unrestricted research grant from the Danish Cancer Society.TRIAL REGISTRATION: not relevant.

AB - INTRODUCTION: Ovarian cancer has the highest mortality rate among gynaecological cancers and is the tenth most frequent cancer among women. 80% of patients with advanced stage disease will experience a progression either during or after treatment.METHODS: This was a retrospective, observational study of all women referred to adjuvant or neoadjuvant treatment for ovarian cancer between 1 June 2013 and 31 May 2014 at two university hospitals in Denmark.RESULTS: We included 142 women diagnosed with ovarian cancer. The median overall survival from diagnosis was 48.5 months (95% confidence interval (CI): 36.6-57.9 months). Median survival after the first, second, third, fourth and fifth progression was 19.3 (95% CI: 13.9-27-3), 11.4 (95% CI: 7.7-18.8), 9.5 (95% CI: 6.3-12.7), 8.3 (95% CI: 7.6-11.5) and 5.6  (95% CI: 2.9-not assessed) months, respectively. Median progression-free survival from diagnosis was 15.6 months (95% CI: 14.3-18.4 months). Median progression-free survival after first, second, third, fourth and fifth progression was 9.2 (95% CI: 7.7-10.6), 6.0 (95% CI: 3.5-7.7), 3.3 (95% CI: 2.6-4.6), 4.9 (95% CI: 3.6-8.3) and 3.0 (95% CI: 2.4-5.7) months, respectively. The most frequently used treatment at first progression was carboplatin and pegylated liposomal doxorubicin (n = 37). The most used non-platinum containing treatment at progression was pegylated liposomal doxorubicin (n = 26) followed by paclitaxel (n = 23).CONCLUSIONS: Ovarian cancer remains a highly aggressive disease with most patients diagnosed in advanced stages. Treatment has not changed much in the past 15 years and the same is evident for the overall survival.FUNDING: Tobias Berg received an unrestricted research grant from the Danish Cancer Society.TRIAL REGISTRATION: not relevant.

KW - Adult

KW - Aged

KW - Antineoplastic Agents/therapeutic use

KW - Carboplatin/therapeutic use

KW - Denmark

KW - Disease Progression

KW - Doxorubicin/analogs & derivatives

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoadjuvant Therapy

KW - Neoplasm Staging

KW - Ovarian Neoplasms/mortality

KW - Paclitaxel/therapeutic use

KW - Polyethylene Glycols/therapeutic use

KW - Retrospective Studies

KW - Treatment Outcome

M3 - Journal article

C2 - 31908253

SN - 0907-8916

VL - 67

JO - Danish Medical Bulletin

JF - Danish Medical Bulletin

IS - 1

ER -

Treatment and outcomes of a Danish ovarian cancer population

Abstract

Keywords

Fingerprint

Cite this